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Abstract
Background: Stem cell (SC) therapies hold
remarkable promise for many diseases, but there is a
significant gulf between public expectations and the
reality of progress toward clinical application. Public
expectations are fueled by stakeholder arguments for
research and public funding, coupled with intense
media coverage in an ethically charged arena. We
examine media representations in light of the
expanding global landscape of SC clinical trials, asking
what patients may realistically expect by way of
timelines for the therapeutic and curative potential of
regenerative medicine?
Methods: We built 2 international datasets: (1) 3,404
clinical trials (CT) containing ‘stem cell*’ from
ClinicalTrials.gov and the World Health Organization’s
International Clinical Trials Registry Search Portal; and
(2) 13,249 newspaper articles on SC therapies using
Factiva.com. We compared word frequencies between
the CT descriptions and full-text newspaper articles
for the number containing terms for SC type and
diseases/conditions. We also developed inclusion and
exclusion criteria to identify novel SC CTs, mainly
regenerative medicine applications.
Results: Newspaper articles focused on human
embryonic SCs and neurological conditions with
significant coverage as well of cardiovascular disease
and diabetes. In contrast, CTs used primarily
hematopoietic SCs, with an increase in CTs using
mesenchymal SCs since 2007. The latter dominated
our novel classification for CTs, most of which are in
phases I and II. From the perspective of the public,
expecting therapies for neurological conditions, there
is limited activity in what may be considered novel
applications of SC therapies.
Conclusions: Given the research, regulatory, and
commercialization hurdles to the clinical translation of
SC research, it seems likely that patients and political
supporters will become disappointed and
disillusioned. In this environment, proponents need to
make a concerted effort to temper claims. Even
though the field is highly promising, it lacks
significant private investment and is largely reliant on
public support, requiring a more honest
acknowledgement of the expected therapeutic
benefits and the timelines to achieving them.
Keywords: stem cell therapy, clinical trials, public
expectations, newspaper coverage, commercialization,
ethics
Introduction
Stem cell (SC) therapies hold remarkable promise, parti-
cularly in the management of diseases and conditions
for which there are currently limited or no treatment
options [1]. As with all emerging technologies, creating
novel applications from an evolving knowledge base is a
slow process. Often development commences in niche
areas, and only after initial success does the technology
expand to broader use. Many SC investigators, therefore,
feel that there is a significant gulf between public expec-
tations and the reality of progress toward clinical SC
application; a phenomenon observed for other novel
biotechnologies [2]. In this paper, we examine this gulf
by comparing public expectations, as represented in
media coverage, with translation of SC research towards
the clinic, as represented in registers of clinical trials
(CT).
This paper examines media coverage in an era of
expanding SC clinical activity around the globe. Media
coverage both shapes and reflects public expectations for
SC research [3]. The media record provides a general
timeline of translational SC research and spikes in atten-
tion that reflect specific events [4]. As media reports are
a major source of health and science information for the
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public [3], they also represent the public face of SC
research and thus the messages on which public expecta-
tions are based. Likewise, examining the current clinical
trial landscape reveals the reality and direction of
ongoing improvements to established SC applications
and the development of new applications based upon
innovative research. While SC transplants are the stan-
dard of care for hematopoietic cancers and are gaining
acceptance in the treatment of burns and corneal disor-
ders, pioneering SC therapies directed at the regeneration
of other tissues and organs (that is, the promise of regen-
erative medicine) are few in number, use adult rather
than embryonic stem cells, and are in the early stages of
clinical investigation.
In this paper, we characterize the gap between public
expectations represented in media coverage and the spec-
trum of ongoing SC clinical trials. We first describe the
influences that can alter expectations for SC research. We
then describe our methods and results, which focus on the
subset of trials that comprise novel regenerative medicine
applications and representations of the types of SCs used
and diseases to be treated or cured. Our discussion con-
textualizes the gap between current realities and expecta-
tions, concentrating on the scientific, regulatory, ethical,
and commercial challenges facing SC research as it pro-
gresses through clinical development to clinical applica-
tion. Our goal is to uncover the nature of the biases in the
public discourse on stem cell research that separates fact
from fiction. This is the first step to creating better com-
munication strategies among the clinical research commu-
nity and the public, patients, and policy makers. The latter
stakeholders need to understand what realistically to
expect by way of timelines for the therapeutic and curative
potential of regenerative medicine.
Background
There are many potential reasons for the public’s high
expectations for SC based therapy [5]; however, advances
in the stem cell arena reported to the public may be
skewed by media coverage that focuses preferentially
upon ethically charged topics [4]. This could fuel overly
optimistic speculation by investigators and patient advo-
cates looking to counter ethical opposition to human
embryonic (hESCs) and fetal SC research, even though
ethical objections have been tempered with the discovery
of induced pluripotent SCs (iPSCs) [6]. Further inflation
of expectations occurs through direct advertising to des-
perate patients by clinics offering unproven SC therapies,
which have sprung up in jurisdictions with lax regulatory
oversight [7] and by dramatic situations portrayed in
popular culture [1,8], such as the growth of multiple
organs from SCs on Grey’s Anatomy.
Inflation of expectations may also result from societal
pressures such as: the potential for economic returns on
research investment, job creation in a new industry, and
the fear that commercial benefits will flow elsewhere in
the absence of a supportive funding and regulatory envir-
onment [5]. The notion of research, largely from aca-
demic centers, as an economic engine has been gaining
momentum since the 1960s when policymakers began
linking innovation with productivity and economic
growth [9]. This argument has fueled support for public
funds for biomedical research, but, in the case of SC
research, Vannevar Bush’s observation may hold that ‘a
belief may be larger than a fact’ [8]. Policy reports claim
SC therapies will, in the foreseeable future, not only
regenerate damaged tissues and organs, but enable the
growth of transplantable organs and combat rising
healthcare costs [10]. Policy-based estimates of economic
return range over orders of magnitude from tens of mil-
lions to billions of dollars [5] while predicted employ-
ment gains vary from tens of thousands to hundreds of
thousands of jobs. Jurisdictions as disparate as India,
China, Japan, Singapore, the UK, Australia and Canada
all signal intense international competition for economic
advantage, each declaring a bid for pre-eminence. For
example, in his parting speech to the Labour Party, for-
mer British Prime Minister Tony Blair declared: ‘How to
be the world’s number one place of choice for bioscience:
if America does not want stem-cell research, we do’ [11].
Yet, contrary to the hype, large-scale corporate invest-
ment in the field has been slow to materialize because of
the lack of proven business and investment models.
Nevertheless, many researchers attempt to temper
expectations and timelines, acknowledging the complexity
of cellular processes and the need for a better understand-
ing of developmental biology [1,12]. Based on the history
of advances in biotechnology, George Daley has recently
stated that, ‘it takes some two decades for a new biotech-
nology advance to translate into widely successful clinical
therapies’ [12]. Given that hESCs were first described in
1998 and iPSCs in 2007, ‘we might anticipate some 10 to
15 years before effective products are developed, thereby
launching the era of regenerative medicine’ [12]. Else-
where, however, Daley has stated: ‘We should be humble
and appreciate it may take us the better part of this cen-
tury to truly harness the power of cells as medicines’ [13].
Regulators are similarly taking a cautionary approach to
emerging applications [14,15], despite building pressures
to accelerate the development of SC therapies. Regulators
share the concerns of many investigators that exaggeration
and hype have real-world consequences, currently mani-
fested by the rise in SC tourism [16] to SC clinics [7].
Services are offered most commonly for neurological
diseases, including multiple sclerosis, stroke, Parkinson’s
disease, spinal cord injury and Alzheimer’s disease, and
cardiovascular diseases [7]. SC tourism has necessitated a
response by the International Society for Stem Cell
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Research (ISSCR) because ‘administering unproven SC
interventions outside a carefully regulated clinical trial
puts individual patients at risk and also jeopardizes the
legitimate progress of translational SC research’ [14].
These scientific, regulatory and commercial challenges are
at odds with public expectations, which seek to increase
the pace of clinical development and have healthcare sys-




We built a dataset of newspaper articles using Factiva.
com (Dow Jones & Co.), a comprehensive database of
major newspapers from the USA and UK, which also
includes all major newspapers in Canada. We searched
without date restrictions for: (‘stem cell’ or ‘stem cells’)
AND (therapy or therapies or therapeutic or therapeu-
tics or treatment or treatments). Factiva identified and
removed duplicates. We then analyzed both our CT
dataset described below (title, brief summary, and
detailed description for each CT) and the full-text news-
paper dataset, using a custom word frequency analysis
program that enabled a set of documents to be searched
using multiple words or phrases, separated by and/or.
The result of each search query was not the number of
times that a search term occurred; rather, it was the
number of documents containing the term(s). We com-
pared word frequencies using c2 analyses in two time
blocks: 1990 to 2000 and 2001 to 2010. While the broad
search strategy may have captured newspaper articles
that were only tangentially related to translational SC
research, our keyword analysis extracted newspaper arti-
cles from this set that specifically referred to SC types
and disease categories.
Clinical trials
We searched the term ‘stem cell*’ in the world’s largest and
most comprehensive database for CTs: ClinicalTrials.gov
and a second portal that captures international trials not
registered with the US National Institutes of Health (NIH):
the World Health Organization’s International Clinical
Trials Registry Search Portal [17]. The latter included trials
from Australia and New Zealand, UK, Brazil, China, India,
South Korea, Cuba, Germany, Iran, Japan, Africa, Sri
Lanka, and The Netherlands. We removed non-SC-related
trials that were nevertheless captured by the search and
duplicates (trials registered in more than one database).
We constructed a database of CT information using
all fields, limiting our analysis to CTs registered before
1 January 2011.
We coded all CTs in the dataset for the principle dis-
ease/condition addressed, and CTs could fall within more
than one category. We then developed inclusion and
exclusion criteria to identify groundbreaking or novel SC
therapies and coded the trials based on their description
supplemented by related publications and websites. The
latter was necessary, for example, to characterize a thera-
peutic agent identified only by its proprietary name in the
trial description.
Our definition of novel SC therapies was CTs that
involved: (1) the use of stem or precursor cells to stimulate
non-hematopoietic organ regeneration (for example, lim-
bal SCs for corneal regeneration or hematopoietic SCs for
cardiac repair); (2) the use of agents to stimulate stem or
precursor cell action for regenerative or therapeutic pur-
poses; (3) the use of established hematopoietic SC trans-
plantation procedures for novel indications (for example,
autoimmune or congenital diseases); (4) the use of novel
agents or processes for stem or precursor cell collection,
purification or expansion; and (5) the use of genetically
modified stem or precursor cells. These categories fall pre-
dominantly within Mason et al.’s definition of regenerative
medicine [18].
We excluded CTs from our ‘novel’ category that were
observational in nature, for example, some CTs measured
circulating endothelial precursor cells without a therapeu-
tic goal; involved an established SC therapy for an estab-
lished indication, most commonly hematopoietic SC
transplantation for hematological malignancies; or investi-
gated supportive measures surrounding an SC therapy, for
example, antibiotics to prevent infection in hematopoietic
SC transplant recipients.
Results
The analysis was based on the total of 13,249 newspaper
articles collected using our broad search strategy and
3,404 CTs from 1978 to 2011. The apparent decline in
CTs from 2009 to 2010 may reflect economic decline
from 2008, but is more likely due to a lag in the registra-
tion of trials. It is worth noting that there was a slight rise
in CTs after 2000, which may be the result of the institu-
tion of stricter registration requirements for acceptance of
CTs for publication [19].
Newspaper articles
Newspaper articles focused mainly on human embryonic
SCs and neurological conditions with significant coverage
of cardiovascular disease and diabetes as well. Newspaper
coverage peaked in 2001 and again in 2005, coinciding
with US President George Bush’s 2001 Directive limiting
the use of federal funds for derivation of new hESC lines
and similar discourse following his re-election at the end
of 2004 (Figure 1A) [4]. Notably, a similar spike in cover-
age did not accompany US President Barack Obama’s
Executive Order, signed 9 March 2009, reversing President
Bush’s Directive. We discussed the framing of the issues in
newspaper coverage around hESC research in a previous
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paper [4]. The key result here is that hESCs dominated
newspaper coverage of SC research, with slight coverage
of the discovery of iPSCs in November 2007, mainly
focused on their being an ‘ethical’ alternative to hESCs
(Figure 1A) [6]. This leaves hESCs front and center in the
public mind with respect to the type of stem cell in clinical
development. In contrast, while newspapers referred to
adult SCs and occasionally their tissue of origin, they
rarely referenced terms such as hematopoietic and
mesenchymal, or synonyms for these such as blood SCs.
In addition, newspaper articles focused disproportionately
on neurological conditions, primarily, multiple sclerosis,
a) 
b) 
Figure 1 Stem cell types in newspapers (A) and clinical trials (B) from 1991 to 2010. The difference in the percentage of newspaper
articles versus clinical trials using keyword synonyms for stem cell types is significant overall as well as between the decades 1991 to 2000 and
2001 to 2010 (P <0.001).
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stroke, Parkinson’s disease, spinal cord injury and Alzhei-
mer’s disease with significant coverage also of cardiovascu-
lar disease and diabetes (Figure 2A). Neurological diseases
were significantly linked to coverage of hESC research and
therapies. Promising research in therapies for ocular con-
ditions such as corneal repair and macular degeneration
received a small but steady amount of coverage from 2000
onwards.
Clinical trials
In contrast, all CTs (n = 3,404) were dominated by use
of adult SCs, primarily hematopoietic SCs, with some
trials using umbilical cord blood derived SCs. There
were an increasing number of trials using mesenchymal
stem cells (MSCs) from 2007 (Figure 1B). The latter
dominated our novel classification for CTs, most of
which were in phases I and II (Figure 3). Figure 4 shows
the global landscape for innovative CTs, with higher
proportions using MSCs in Asia and the Middle East.
As of 2011, iPSCs had not entered CTs, and the best-
known trial using hESCs, started in October 2010 by
Geron for spinal cord injury, was halted in November
2011 after use in only four trial subjects. Three additional
trials by Advanced Cell Technology (Santa Monica, CA,
USA) began in July 2011: two using retinal pigment
epithelial cells derived from hESCs for Stargardt’s macular
dystrophy and one for dry age-related macular degenera-
tion [20]. CTs for cancers and graft-versus-host disease
(GVHD), which composed most of the ‘other diseases’
category, dominated the SC CT landscape (Figure 2B).
Nevertheless, there was a steady increase in CTs for cardi-
ovascular disease beginning in 2001 and a small number
of trials for neurological, ocular conditions and diabetes
(note that the key word analysis for diabetes also captured
CTs for associated morbidities such as diabetic foot). Our
detailed examination of novel CTs was dominated by trials
using MSCs and for conditions other than hematological
cancers.
Our criteria for novel SC CTs resulted in the selection of
639 (19%) CTs that, if successful, would become the next
generation of regenerative treatments. A total of 512 of
these CTs clearly indicated study phase, and, of these, the
majority were safety trials in phases I or II (Figure 4). Only
54 novel CTs were in phases II/III or III and 17 were in
phases III/IV or IV (Table 1). The majority of clinical trials
in phase III/IV (n = 11) used drug treatments to activate
endothelial progenitor cells for therapeutic purposes in
cardiovascular diseases (which may be associated with
other diseases such as diabetes and ankylosing spondylitis).
A further three advanced stage trials used stents to facili-
tate vascular repair by capturing endothelial progenitor
cells in the stent and three trials addressed metabolic
syndrome, critical limb ischemia, and breast deformities
following a lumpectomy.
While the public and policymakers expect therapies for
neurological conditions, there was limited activity in
what may be considered novel application of SC thera-
pies. Among the novel CTs, only 69 trials addressed neu-
rological conditions (Table 2) and only 1 in our dataset,
the Geron (Menlo Park, CA, USA) trial, used hESCs. The
majority of trials used hematopoietic stem cells or MSCs.
For example, clinical trials for multiple sclerosis used
autologous transplantation of MSCs or hematopoietic
SCs following chemotherapy to achieve immunomodula-
tion and facilitate regeneration of the central nervous sys-
tem. Two trials, being conducted in India, for Parkinson’s
disease used MSCs.
The majority of novel trials were publicly funded; how-
ever, some industry involvement was evident. Industry
trials targeted both orphan and common diseases. Three
phase I trials by StemCells Inc. (Newark, CA, USA)
employed cultured allogeneic neural SCs (HuCNS-SC) to
treat Pelizaeus-Merzbacher disease and neuronal ceroid
lipfuscinosis. Ischemic stroke was the focus of significant
industry involvement with 6 of 18 CTs sponsored by
Stem Cell Therapeutics (Toronto, Canada), ReNeuron
(Guildford, UK), and Stempeutics Research (Bangalore,
India). The phase I trial by ReNeuron used a manufac-
tured neural SC line (CTX cells) while the four Stem Cell
Therapeutics trials attempted to use a proprietary drug
(NTx-265) to promote neural regeneration. However,
news reports indicated the lack of demonstrable effect in
the latter CTs [21].
Of all the other diseases highlighted in the media, 208
CTs were for cardiovascular disease: 75% targeted the
heart and 25% the peripheral vascular system. Almost all
of these trials involved MSCs, mobilization of hemato-
poietic SCs, other purified bone marrow-derived SCs, or
endothelial progenitor cells for regenerative and suppor-
tive purposes. There were 27 novel trials for diabetes
mellitus, and these CTs attempted to treat both Type I
and Type II diabetes using hematopoietic and MSCs
from adipose tissue, umbilical cord blood, and bone mar-
row. Private sector companies were involved as colla-
borators or sponsors in eight of the trials, including
Osiris Therapeutics (Columbia, MD, USA), Adistem
(Hong Kong, China), Transition Therapeutics (Toronto,
Canada), Cellonis Biotechnology (Beijing, China), and
Genzyme (Cambridge, MA, USA).
Discussion
Innovative biomedical technologies are prone to ‘social
bubbles’ where categories of ‘enthusiastic supporters
weave a network of reinforcing feedbacks that lead to
widespread endorsement and extraordinary commitment
by those involved in the project’ [22]. The enthusiasm of
stakeholders such as researchers, the public, politicians,
and funders in promoting optimistic timelines often
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masks the slow uptake of clinical applications and tech-
nologies within health systems, whether in biotechnology
[23,24] in general or, more specifically, in genomics [25]
or SC research. Our results show that there is a large gap
between public expectations and clinical realities, with
public representations focused on hESCs and on cures
a) 
b) 
Figure 2 Categories of diseases in newspapers (A) and clinical trials (B) from 1991 to 2010. The difference in the percentage of
newspaper articles versus clinical trials using keyword synonyms for stem cell types is significant overall as well as between the decades 1991 to
2000 and 2001 to 2010 (P < 0.001).
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for neurological conditions. There is little awareness of
the dominant clinical applications that use hematopoietic
SCs and increasingly use MSCs. This leaves patients, des-
perately hoping for life-altering therapies, vulnerable to
unscrupulous providers of unproven and expensive treat-
ments. Indeed, there is a direct correlation between the
numerous therapies for neurological conditions adver-
tised by SC tourism clinic providers and media coverage
Figure 3 Study phases of novel clinical trials. Note that only 512 out of 639 clinical trials clearly indicated study phase. The drop in clinical
trials in 2010 may be due to a lag in registration of clinical trials in databases by investigators.
Figure 4 Global map of innovative clinical trials representative of the future of regenerative medicine, indicating the proportion using
mesenchymal stem cells (MSCs; in red). Numbers denote the total number of novel clinical trials in the region; small circles denote regions
with one to three novel clinical trials.
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dominated by neurological diseases as described in the
study by Lau et al. [7].
Why do therapies take so long to reach patients?
Stem cell biology is highly complex and variable; using
cells as therapeutic agents bears few parallels to the use of
small molecule drugs. This creates significant challenges
for regulators developing the testing necessary to assure
the quality of novel technologies and therapies, for busi-
nesses that require reproducible large scale production
capacity, and for the health systems that need to find the
funds for what will likely be personalized and expensive
therapies. As an example, there are valid concerns about
manufacturing consistency of cell cultures and the genetic
stability of cell lines. Both hESCs and iPSCs have been
shown to experience genetic and phenotypic drift in long-
term in vitro culture. There are further concerns about
iPSCs due to the degree to which differentiated adult cells
must be manipulated to become pluripotent [26,27].
Given that there is a potential for late tumor formation
resulting from inadvertent mutagenesis in the creation of
SC products, prolonged monitoring of animals used in
preclinical studies and long-term monitoring of CT parti-
cipants will be required. SCs that are manipulated or man-
ufactured or used in a non-homologous manner [28]
require more stringent oversight to ensure the safety of
the recipient.
Regulators are still developing systems specifically for
complex cell therapies. The conventional preclinical reg-
ulatory studies for absorption, distribution, metabolism,
excretion, and toxicity of drugs cannot be applied to cell-
based therapies, in part because of an inability to track
differentiation and migration of transplanted cells [15].
In contrast to drugs, SC based therapies may result in
Table 1 Novel clinical trials (CTs) in phase II/III, phase III, phase II/IV or phase IV (n = 71) (note that phase II/IV and
phase IV trials all fell in the drug treatments, stents or other categories (n = 17))
Clinical trial subject No. of
CTs
Country
Bone conditions 3 Iran, USA
Cardiovascular disease 29 Brazil, Canada, China, Finland, Germany, India, Iran, Italy, Mexico, The Netherlands, Russia, South
Korea, UK, USA
Cartilage damage 2 Egypt, South Korea
Crohn’s Disease 4 UK, USA
Diabetes 2 India, China
Multiple sclerosis 1 USA
Ocular surface disease 2 Malaysia, Thailand
Scleroderma 3 USA
Spinal cord injury 1 India
Drug treatments for stem cell
mobilization
11 China, Germany, Italy, South Korea, Turkey, USA
Stents for capturing endothelial
progenitor cells
3 China, The Netherlands, Poland
Other (mainly graft-versus-host disease) 3 India, Germany, UK
Table 2 Novel clinical trials (CTs) for neurological conditions (n = 69)
Clinical trial subject No. of CTs Country
Amyotrophic lateral sclerosis 7 China, Israel, Spain, USA
Cerebral palsy 3 Mexico, South Korea, USA
Cerebral palsy using MSCs 3 China, India
Diabetic neuropathy 3 Germany, Mexico, USA
Ischemic Stroke 18 Brazil, Canada, France, India, Malaysia, Russia, Spain, Taiwan, UK, USA, Russia
Multiple sclerosis 12 Canada, Israel, Spain, UK, USA
Neuronal ceroid lipfuscinosis 2 USA
Parkinson’s Disease 2 India
Pelizaeus-Merzbacher Disease 1 USA
Spinal cord injury (non-hESC) 5 Egypt, India, USA
Spinal cord injury (hESC) 1 USA
Traumatic brain injury 3 Canada, India, USA
Other 10 Brazil, China, The Netherlands, South Korea, Thailand, USA
hESCs = human embryonic stem cells; MSCs = mesenchymal stem cells.
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long-term engraftment, with amplification of the admi-
nistered dose of SC and further growth and differentia-
tion of the SC progeny. Regulators, in consultation with
the SC research community, are attempting to develop a
proportionate response which will balance patient safety
yet will not stifle innovation in this field.
Developing or modifying regulatory pathways takes time,
trust, and communication between regulators and the
research community, all of which are undermined by hype
[15,28] or public representations of SC research that do
not reflect its current state and the realistic developmental
timelines for specific diseases or conditions, as documen-
ted by this study. Even with cooperation between SC
researchers and regulators, oversight may prove difficult in
a translational environment that has gone global, as
demonstrated in Figure 3. Significantly, our results show
that CTs testing novel SC approaches are occurring
beyond the borders of North America and Europe. Indeed,
while there are SC trials for novel application increasingly
being registered from sites in India, China, and Iran, and
to a lesser extent in Brazil, Mexico and Malaysia, these
may use SC with only rudimentary characterization or for
situations with as yet poorly understood biological ratio-
nale; the very types of trials concerning to the ISSCR. Ethi-
cal issues and conflicts of interests are more likely to arise
where inadequately developed regulatory and consent fra-
meworks exist. This will be of special concern in an arena
such as the complex regulatory environment for cell thera-
pies that necessitate long-term monitoring and follow-up
for participants.
Media reporting of therapeutic benefits, especially for
neurological conditions, may exacerbate the ‘therapeutic
misconception’ in all countries [29]. While our analysis
demonstrates that most SC CTs are in phases I or II, parti-
cipants may conflate such early stage safety trials with
therapeutic benefit. This mistaken therapeutic belief,
which undermines informed consent, may arise from
poorly structured consent forms or from the descriptions
of CTs in trial registries [30]. In reality, most therapies fail
in phase I and II, and those that are proven both safe and
effective take between US$200 million and US$1 billion in
investment over a span of 10 to 15 years before they are
approved and adopted by the medical community [31].
A further challenge highlighted in our results of public
versus private support of trials is that commercial enter-
prise has been slow to move into the cell therapy arena,
primarily because of the lack of easily defined business
models [32]. Cell therapies are not drugs and require the
development of new manufacturing and distribution sys-
tems. While a few allogeneic products with central manu-
facturing have been developed, most notably Carticel from
Genzyme and Apligraf from Organogenesis, the closest
model to many of the current CTs is hematopoietic SC
transplantation (HSCT). HSCT is a high-cost, highly
specialized treatment, requiring significant infrastructure
and an interdisciplinary network of healthcare profes-
sionals [33,34]. Its global use is highly correlated with
gross national income, healthcare expenditure and the
availability of transplant teams. Given these system costs,
the bar for therapeutic value, which compares the benefits
of SC therapies with existing treatments, will be high. The
model also belies the anticipated health system savings
promised by proponents of SC research. These financial
pressures, such as the scientific and regulatory issues, are
absent from media reports and are hidden from public dis-
course, contributing to the disconnected state of current
expectations.
Conclusions
Given the research, regulatory, commercialization and
health system hurdles involved in the clinical translation
of SC research, it seems likely that patients and political
supporters will become disappointed and disillusioned.
In this environment, proponents need to make a con-
certed effort to temper claims. It is simply ‘unfair to
raise people’s hopes to unrealistic levels when they and
their families are desperate for treatments that will
relieve their suffering and improve their health’ [35].
Even though the field is highly promising, the road to
the clinic is long and hard, and the technology may yet
develop in unanticipated ways. For a field that, lacking
significant private investment, is largely reliant on public
support, there needs to be a more honest acknowledge-
ment of the expected therapeutic benefits and the time-
lines to achieving them.
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